Fig. 3From: Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-RegistryOS of patients with HER2-low tumors and patients with completely HER2-negative tumors (HER2-0) in (A) the HR-negative [n = 320] and (B) the HR-positive subgroup [n = 1058], respectivelyBack to article page